BEND5: A Potential Drug Target and Biomarker for Glioblastoma multiforme

Target Name: BEND5

NCBI ID: G79656

BEND5

BEND5: A Potential Drug Target and Biomarker for Glioblastoma multiforme

Introduction

Glioblastoma multiforme (GBM) is a highly aggressive form of brain cancer that accounts for approximately 10% of all human malignant tumors. Despite advances in surgical and radiation treatments, the survival rate for GBM remains dismal and has not changed significantly in the last decades. Therefore, there is a high demand for new treatments and biomarkers that can aid in the diagnosis, prognosis, and treatment of GBM. BEND5, a protein containing 5 domains, has been identified as a potential drug target and biomarker for GBM. In this article , we will discuss the characteristics of BEND5, its potential implications as a drug target, and its potential as a biomarker for GBM.

Characteristics of BEND5

BEND5 is a 21-kDa protein that contains 5 domains: a N-terminal alpha-helix, a middle T-loop, a variable G-loop, a C-terminal alpha-helix, and a G-quadruple. The protein has a pI of 9.0 and a predicted localization in the cell membrane. BEND5 is an evolutionarily conserved protein and has been identified in various organisms, including human, mouse, and rat.

Potential Implications as a Drug Target

Glioblastoma multiforme is a refractory disease, which means that conventional treatments have limited efficacy. Therefore, there is a high demand for new treatments that can target this disease. BEND5 has been shown to be involved in various cellular processes, including cell adhesion, migration, and invasion. Therefore, it is a potential drug target for GBM.

BEND5 has been shown to play a role in the development and progression of GBM. For example, studies have shown that BEND5 is overexpressed in GBM tissues and that inhibition of BEND5 can lead to regression of GBM tumors. Additionally, BEND5 has been shown to be involved in the regulation of cell survival, as it has been shown to play a role in the cell cycle and apoptosis. Therefore, targeting BEND5 may be an effective way to treat GBM.

Potential as a Biomarker

BEND5 has also been shown to be a potential biomarker for GBM. GBM tumors are characterized by the expression of various proteins, including BEND5. Therefore, measuring the expression of BEND5 may be an effective way to diagnose GBM. Additionally, since BEND5 is overexpressed in GBM tissues, downregulation of BEND5 may be an effective way to target GBM tumors.

Conclusion

In conclusion, BEND5 is a protein containing 5 domains that has been identified as a potential drug target and biomarker for Glioblastoma multiforme. Its potential as a drug target and biomarker makes it an attractive target for future research. Further studies are needed to confirm its potential and to develop new treatments for GBM.

Protein Name: BEN Domain Containing 5

Functions: Acts as a transcriptional repressor (PubMed:23468431)

The "BEND5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BEND5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets